Patents

US 11229602 B2: Formulations for treating bladder cancer

Granted
2022-01-25
Filed
2017-01-09 application 16066836
Type
Utility · 16 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.

Source: PVGPATDIS, file of 2026-04-10 (ipg220125.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
WESTERN UNIVERSITY OF HEALTH SCIENCES 19 patentsUS company or organizationPomona, CAWESTERN UNIVERSITY OF HEALTH SCIENCES State business registration EXACT high confidence: identical full name and state
Western University of Health Sciences College or university EXACT high confidence: identical full name and state
WESTERN UNIVERSITY OF HEALTH SCIENCES Nonprofit EXACT high confidence: identical full name and state
PVGPATDIS, file of 2026-04-10
TESORX PHARMA, LLC 5 patentsUS company or organizationMenlo Park, CATesoRx Pharma, LLC Form D issuer EXACT high confidence: identical full name and statePVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Guru V. BetageriChino Hills, CA9PVGPATDIS, file of 2026-04-10
Natarajan VENKATESANDiamond Bar, CA1PVGPATDIS, file of 2026-04-10
Michael G. OefeleinBakersfield, CA2PVGPATDIS, file of 2026-04-10
Ramachandran ThirucoteAtherton, CA9PVGPATDIS, file of 2026-04-10
Nitin K. SWARNAKARTarrytown, NY1PVGPATDIS, file of 2026-04-10
Teresa B. HongEl Monte, CA4PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K9/1277PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P35/00PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2020-11-09Assignment
Assignment of assignor's interest
HONG, TERESA signed 2020-11-05
THIRUCOTE, RAMACHANDRAN signed 2020-11-05
SWARNAKAR, NITKIN KUMAR signed 2020-11-06
TESORX PHARMA, LLC MENLO PARK, CA54309/596ECORSEXC, file of 2026-09-25
2018-12-05Assignment
Assignment of assignor's interest
BETAGERI, GURU V. signed 2018-07-06WESTERN UNIVERSITY OF HEALTH SCIENCES POMONA, CA47678/190ECORSEXC, file of 2026-09-25
2018-12-05Assignment
Assignment of assignor's interest
VENKATESAN, NATARAJAN signed 2018-07-06
OEFELEIN, MICHAEL G. signed 2018-07-11
TESORX PHARMA, LLC MENLO PARK, CA47678/124ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.